Clinical trial
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in…
NCT05500222 · Madrigal Pharmaceuticals, Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT05500222 |
|---|---|
| Title | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) |
| Official title | A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES) |
| Lead sponsor | Madrigal Pharmaceuticals, Inc., Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | NASH, Cirrhosis, Liver |
| Intervention type | Drug |
| Interventions | Resmetirom, Placebo |
| Enrollment | 700 |
| Start date | Aug 26, 2022 |
| Primary completion | Dec 1, 2026 |
| Completion | Jan 1, 2027 |
| First posted | Aug 15, 2022 |
| Last update posted | Jun 11, 2025 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: